MOMA Therapeutics

aid: moma-therapeutics
name: MOMA Therapeutics
description: 'MOMA Therapeutics is a Cambridge, Massachusetts drug-discovery company founded in 2020 that builds precision
  medicines against molecular machines — the highly dynamic proteins that convert chemical energy stored in cells into regulatory
  work such as protein transport, DNA repair and degradation, and whose constant conformational shape-shifting has historically
  made them undruggable. Its proprietary KNOMATIC platform combines advanced structural frameworks and functional-genomics
  target validation with high-throughput fragment and DNA-encoded-library screening, CRISPR gene editing, artificial intelligence
  for detecting dynamic conformational patterns, and machine-learning lead optimisation, all built against a continually expanding
  structure-function knowledge base. The company launched in April 2020 with an $86 million Series A led by Third Rock Ventures,
  added a $150 million Series B in May 2022, and has taken two wholly owned oncology assets into the clinic: MOMA-313, a selective
  inhibitor of the polymerase theta (Polθ) helicase domain for homologous- recombination-deficient tumours, which entered
  Phase 1 in August 2024; and MOMA-341, a potent and selective WRN helicase inhibitor for microsatellite-unstable and TA-repeat-expanded
  tumours, which dosed its first Phase 1 patient in July 2025. It also runs a five-year discovery collaboration with Roche
  announced in January 2024, an oncology collaboration and licence agreement with Bayer signed in October 2024, and an exclusive
  licence for a selective PARP1 inhibitor announced in January 2025. MOMA Therapeutics runs no developer program and publishes
  no product API, developer portal, API reference or machine-readable specification. The only machine-readable surface reachable
  without credentials is the WordPress REST content API behind momatx.com, catalogued here.'
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: true
  label: Hosted service · you call their endpoint
  confidence: high
  source:
  - openapi
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: open
  trial: false
  try_now: false
  public: true
  label: Open access
  confidence: medium
  source:
  - authentication
  - rate-limits
  - security
  generated: '2026-09-02'
  method: derived
image: https://momatx.com/wp-content/uploads/2025/03/logo-moma.png
url: https://raw.githubusercontent.com/api-evangelist/moma-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enriched
specificationVersion: '0.23'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Oncology
- Precision Medicine
- Life Sciences
- Structural Biology
- Machine Learning
- content-api
tags_raw:
- Company
- biotechnology
- pharmaceuticals
- drug-discovery
- oncology
- precision-medicine
- life-sciences
- structural-biology
- machine-learning
- content-api
- Machine-Learning
apis:
- aid: moma-therapeutics:momatx-com-website-wordpress-rest
  name: MOMA Therapeutics Website (WordPress REST)
  description: 'The public WordPress REST API (wp-json) of the MOMA Therapeutics website at momatx.com: the route index of
    the site''s content management system, catalogued as one site surface rather than as separate APIs.'
  baseURL: https://momatx.com/wp-json
  tags:
  - WordPress
  x-surface: platform-generated
  properties:
  - type: Documentation
    url: https://momatx.com/wp-json
  x-platform: wordpress
  x-platform-surface: rest
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://momatx.com/
- type: About
  url: https://momatx.com/moma/
- type: Science
  url: https://momatx.com/science/
- type: Pipeline
  url: https://momatx.com/pipeline/
- type: Team
  url: https://momatx.com/team/
- type: News
  url: https://momatx.com/news-feed/
- type: Blog
  url: https://momatx.com/posts/category/blog/
- type: BlogRSS
  url: https://momatx.com/feed/
- type: PressReleases
  url: https://momatx.com/posts/category/press-release/
- type: Careers
  url: https://momatx.com/join-us/
- type: PrivacyPolicy
  url: https://momatx.com/privacy-policy/
- type: TermsOfService
  url: https://momatx.com/terms/
- type: LinkedIn
  url: https://www.linkedin.com/company/momatx
- type: Twitter
  url: https://twitter.com/moma_tx
- type: YouTube
  url: https://www.youtube.com/channel/UCqBg_d0f0IqXUDbzADjcI1g
- type: SecondaryMarket
  url: https://forgeglobal.com/moma-therapeutics_stock/
- type: Authentication
  url: authentication/moma-therapeutics-authentication.yml
- type: Conventions
  url: conventions/moma-therapeutics-conventions.yml
- type: Conformance
  url: conformance/moma-therapeutics-conformance.yml
- type: ErrorCatalog
  url: errors/moma-therapeutics-problem-types.yml
- type: Lifecycle
  url: lifecycle/moma-therapeutics-lifecycle.yml
- type: DataModel
  url: data-model/moma-therapeutics-data-model.yml
- type: Packages
  url: packages/moma-therapeutics-packages.yml
- type: DomainSecurity
  url: security/moma-therapeutics-domain-security.yml
- type: RateLimits
  url: rate-limits/moma-therapeutics-rate-limits.yml
- type: Plans
  url: plans/moma-therapeutics-plans-pricing.yml
- type: LLMsTxt
  url: llms/moma-therapeutics-llms.txt
- type: AgentSkill
  url: skills/_index.yml
x-enrichment:
  date: '2026-08-26'
  status: enriched
  artifacts_added: 38
  pass: local-v1